Question explored with the scientific record
Conversation so far
- 1 Does ivermectin inhibit influenza viral replication
- 2 Are there safer, evidence-based antivirals for flu besides ivermectin?
Answered on this page ↓
Are there safer, evidence-based antivirals for flu besides ivermectin?
The short version: yes. Baloxavir and oseltamivir have real human trial data; neither is a free lunch, and "safer than ivermectin" is a low bar nobody has actually measured against.
Baloxavir is a single oral dose. In high-risk flu patients it cut symptom time to a median of 73 hours versus 102 on placebo [1]. Against oseltamivir it was only numerically faster, not statistically so [1]. Oseltamivir's own trial record is modest: it reduced viral shedding and improved health in healthy adults [3], and higher doses bought no mortality or clearance gain in hospitalized patients [7].
Safety is where the honesty gets uncomfortable. The baloxavir safety picture here comes from a voluntary reporting database, which detects almost nothing by design [2]. It flagged liver dysfunction and bleeding signals, concentrated in children [2]. Resistance is real: the I38T mutation drops baloxavir susceptibility 30 to 50 fold [4], and a newer D27G change cuts it about 12 fold while keeping the virus fit [5].
| Drug | Best human result here | Main catch |
|---|---|---|
| Baloxavir | 73 vs 102 h symptoms, high-risk [1] | Liver/bleeding signals, pediatric [2]; resistance [4][5] |
| Oseltamivir | Less shedding, better health [3] | Modest; higher dose no better [7] |
| Zanamivir | ~0.6 day faster in adults [6] | No reduction in pneumonia, otitis, sinusitis [6] |
Zanamivir is the mildest: about half a day faster in adults, nothing in children, and no drop in the complications that matter [6].
My call: baloxavir is the strongest single-dose option on symptom relief, oseltamivir the best-studied, and neither has been compared head-to-head against ivermectin, so "safer" is unproven. Confidence: moderate on efficacy, low on comparative safety.
Sources used 7
-
LB15. Vaccine Effectiveness of Flucelvax Relative to Inactivated Influenza Vaccine During the 2017–18 Influenza Season in Northern California
Four abstracts: C. auris had high 90-day mortality; IIV4-HD showed noninferiority and superior B-lineage response; cell- and egg-based IIV had no significant difference; baloxavir shortened influenza symptom time versus placebo in high-risk patients.
DOI: 10.1093/ofid/ofy229.2189 -
Safety evaluation of baloxavir marboxil: analysis and discussion utilizing real adverse events from the FAERS database
This study evaluates the safety of baloxavir marboxil by analyzing adverse drug events reported in the FAERS database, identifying significant safety signals including hemorrhagic complications and liver dysfunction, particularly in pediatric populations.
DOI: 10.1186/s40360-025-00940-0 -
ANTIVIRAL TREATMENT OPTIONS FOR COVID-19 BY REDUCTION OF VIRAL LOAD AND VIRAL SHEDDING
This study explores potential antiviral treatment options for COVID-19 by examining their effectiveness in reducing viral load and shedding, drawing parallels with existing influenza treatments.
DOI: 10.32553/ijmbs.v4i6.1201 -
Characterization of influenza virus variants induced by treatment with the endonuclease inhibitor baloxavir marboxil
This study characterizes influenza virus variants that emerged during treatment with the endonuclease inhibitor baloxavir marboxil, revealing that the PA I38T mutation significantly reduces susceptibility to the drug while impairing viral fitness.
DOI: 10.1038/s41598-018-27890-4 -
Emergence of the novel PA-D27G mutation conferring reduced baloxavir susceptibility in influenza A viruses circulating in China, 2018–2025
Large-scale genomic surveillance and functional analyses identify D27G in the PA endonuclease of H1N1pdm09 as a baloxavir resistance mutation that reduces baloxavir susceptibility by ~12.4-fold while preserving replication fitness, with global prevalence <0.1% and rare occurrenc…
DOI: 10.1080/22221751.2026.2620222 -
Zanamivir for influenza in adults and children shows limited benefit for treatment of symptomatic influenza and no effect on relevant complications
A commentary reanalyzing full clinical study reports on zanamivir for influenza in adults and children, showing limited symptomatic benefit in adults, no clear reduction in major complications, and modest but inconsistent prophylactic effects, with notable uncertainties.
DOI: 10.1136/ebmed-2014-110046 -
Alternative Regimens of Neuraminidase Inhibitors for Therapy of Hospitalized Adults with Influenza: A Systematic Review of Randomized Controlled Trials
In a systematic review of seven randomized trials (1579 hospitalized influenza patients), alternative neuraminidase inhibitor regimens were equally safe but did not significantly change mortality, time to clinical resolution, or viral clearance versus standard-dose oseltamivir.
DOI: 10.1007/s12325-020-01347-5